Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841969 | 1.00 | MMP7 (0.48) | MMP7ITGB3ITGA2BMMECA2 | |
| SCHEMBL6739658 | 0.89 | TSHR (0.45) | MMP13 | |
| SCHEMBL6739657 | 0.89 | TSHR (0.45) | MMP13 | |
| SCHEMBL1329533 | 0.87 | SLC1A3 (0.56) | MMP7ITGB3ITGA2BMMECA2 | |
| SCHEMBL6738805 | 0.84 | MMP7 (0.46) | MMP7ITGB3ITGA2BMMESLC1A3 | |
| SCHEMBL6737757 | 0.84 | MMP7 (0.46) | MMP7ITGB3ITGA2BMMESLC1A3 | |
| SCHEMBL6738450 | 0.82 | MME (0.48) | MMP7ITGB3ITGA2BMMECA2 | |
| SCHEMBL6738452 | 0.82 | MME (0.48) | MMP7ITGB3ITGA2BMMECA2 | |
| SCHEMBL7300504 | 0.81 | MMP7 (0.64) | MMP7ITGB3ITGA2BSLC1A3SLC1A2 | |
| SCHEMBL7558929 | 0.80 | ITGB3 (0.38) | MMP7ITGB3ITGA2BF2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | MMP7 1261/4885ITGB3 38/4885ITGA2B 282/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | MMP7 1581/4885ITGB3 55/4885ITGA2B 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.